Unsupervised clustering to classify patients with candidemia in intensive care: algorithmic tautology or the generation of highly anticipated new data? - Scorecard - MDSpire
Clinical Scorecard: Unsupervised Clustering of Intensive Care Patients With Candidemia: Circular Algorithm or Valuable New Insights?
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: Unsupervised Clustering of Intensive Care Patients With Candidemia
Key Mechanisms
The authors report data-derived phenotypes with distinct clinical and microbiological features. Phenotype 1 is defined by hematological malignancy, neutropenia, high fever, and low leukocyte counts; Phenotype 2 is the cirrhotic/digestive cluster.
Target Population
Patients or participants described in the source article.
Care Setting
Care setting described in the source article.
Key Highlights
The authors report that clustering identified quantitative patient subgroups and microbiological associations, including enrichment of Candida glabrata in Phenotype 2 and Candida parapsilosis in Phenotype 3.
Phenotypes 1 and 2 had comparably high mortality despite differing clinical characteristics.
After SAPS II was removed from clustering, Phenotype 1 remained identifiable, with mortality of 70.1% versus 72.9% in the original model.
Without SAPS II, Phenotypes 2 and 3 were less distinct, with patient redistribution between groups.
The authors acknowledge retrospective design and lack of external validation as study limitations.
Guideline-Based Recommendations
Diagnosis
The article discusses phenotype characterization through unsupervised clustering; it does not provide diagnostic criteria for candidemia.
Management
The authors propose phenotype-stratified trials: Phenotype 3 for studies of shorter antifungal regimens or novel agents, and Phenotypes 1 and 2 for studies of combination therapy or immunomodulatory approaches.
Monitoring & Follow-up
Risks
The authors identify retrospective design and lack of external validation as limitations.
Patient & Prescribing Data
Critically ill patients with candidemia; the article does not provide prescribing instructions or dosing data.
In a target trial emulation, short-course antifungal therapy was not significantly associated with 90-day mortality in non-complicated candidemia. The authors also propose phenotype-stratified trials; no treatment recommendation is established.
Clinical Best Practices
The authors propose future studies that first define biological and microbiological clusters without composite severity scores, then stratify those clusters by severity.
The authors suggest incorporating transcriptomic, proteomic, or metabolomic biomarkers in future phenotype characterization.
The authors state that severity scores can be included when the objective is to characterize the complete clinical syndrome at presentation.
